USFDA Guidance: Hemodialysis Blood Tubing Sets – Premarket Notification (510(k)) Submissions

Sharan Murugan
1 hour ago
3 min read

Hemodialysis blood tubing sets are critical components of the extracorporeal blood circuit used during hemodialysis treatment. Manufacturers submitting a Premarket Notification (510(k)) for these devices should provide sufficient information to demonstrate that the device is safe, effective, and substantially equivalent to a legally marketed predicate device. The Hemodialysis Blood Tubing Sets – Premarket Notification (510(k)) Submissions outlines recommendations for device description, performance testing, biocompatibility, sterility, packaging, shelf life, and labeling to support complete 510(k) submissions.

Scope

The guidance applies to hemodialysis blood tubing sets regulated under 21 CFR 876.5820, as well as the associated product codes for blood tubing sets and blood circuit accessories. It supplements general 510(k) submission requirements by providing recommendations specific to these medical devices.

The guidance applies only to blood tubing sets used as part of the extracorporeal blood circuit. It does not include vascular access devices, such as hemodialysis catheters, or tubing used for peritoneal dialysis.

Device Description

Manufacturers should provide a comprehensive description of the device, including the overall system, labeled diagrams, specifications for each model, and the functionality of individual components such as infusion ports, drip chambers, heparin lines, transducer protectors, and priming sets.

The submission should also identify compatible hemodialysis delivery systems and specify whether arterial and venous blood lines are supplied separately or together as a complete set.

A comparison with a legally marketed predicate device should also be included, highlighting similarities and differences in intended use, materials, design, biocompatibility, and performance characteristics.

Performance Testing

The guidance recommends performance testing to demonstrate that the blood tubing set performs as intended and supports substantial equivalence to the predicate device.

Recommended evaluations include pressure leak testing, pump segment endurance testing, injection port durability, priming volume assessment, tensile strength testing, transducer protector leakage testing, clamp performance, hemocompatibility assessment for applicable designs, and resistance to tubing kinking.

Manufacturers should also evaluate device performance on compatible hemodialysis delivery systems using a blood analog fluid to verify tubing integrity and confirm proper pump segment performance.

Device Materials and Biocompatibility

The submission should describe all materials used in manufacturing the blood tubing set, including colorants, plasticizers, and additives. Materials should be identified according to whether they have direct or indirect contact with circulating blood.

Where identical materials and manufacturing methods cannot be justified using a legally marketed device, appropriate biocompatibility testing should be provided. Recommended evaluations may include cytotoxicity, sensitization, irritation, systemic toxicity, pyrogenicity, hemocompatibility, genotoxicity, chronic toxicity, and carcinogenicity, or an appropriate scientific justification if specific testing is not performed.

Sterility

Manufacturers should provide sterilization information demonstrating that the device meets appropriate sterility assurance requirements. The guidance also recommends pyrogenicity testing for blood-contacting devices and submission of information describing the testing method, extraction procedure, testing endpoint, and applicable reference standards.

Shelf Life and Packaging

Hemodialysis blood tubing labels should include an expiration date supported by shelf-life studies. Manufacturers are encouraged to provide performance testing on aged samples together with package integrity testing to demonstrate that sterility and non-pyrogenicity are maintained throughout the proposed shelf life.

Accelerated aging studies may be used when supported by appropriate scientific justification.

Labeling

Proposed labeling should clearly describe the device, its intended use, compatible hemodialysis delivery systems, operating characteristics, and directions for use.

The guidance recommends including information describing package contents, tubing dimensions, priming volume, maximum operating pressures, compatibility information, single-use status, sterility, and non-pyrogenicity. Colour coding of arterial and venous tubing connectors is also recommended to support safe device identification.

Manufacturers should include appropriate warnings regarding tubing kinking and reinforce that the device is intended for single use only. Outer package labeling should additionally provide storage conditions, sterility information, lot number, sterilization date, and expiration date. Instructions for use should encourage appropriate user training and identify the intended patient population.